Technical Analysis for MORF - Morphic Holding, Inc.

Grade Last Price % Change Price Change
D 33.13 -0.98% -0.33
MORF closed down 3.15 percent on Monday, March 18, 2024, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish -0.98%
MACD Bearish Centerline Cross Bearish -0.98%
NR7 Range Contraction -0.98%
NR7-2 Range Contraction -0.98%
Lower Bollinger Band Walk Weakness -0.98%
Lower Bollinger Band Touch Weakness -0.98%
Oversold Stochastic Weakness -0.98%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.10%
Pocket Pivot Bullish Swing Setup -4.10%
NR7 Range Contraction -4.10%

   Recent Intraday Alerts

Alert Time
Fell Below Lower Bollinger Band 2 minutes ago
Fell Below Previous Day's Low 2 minutes ago
Down 2 % 2 minutes ago
Down 1% 2 minutes ago
60 Minute Opening Range Breakout about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Gastrointestinal Cancers Integrin

Is MORF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 63.0825
52 Week Low 19.345
Average Volume 561,162
200-Day Moving Average 39.10
50-Day Moving Average 33.80
20-Day Moving Average 36.25
10-Day Moving Average 35.69
Average True Range 1.89
RSI (14) 41.86
ADX 22.62
+DI 13.88
-DI 22.30
Chandelier Exit (Long, 3 ATRs) 34.34
Chandelier Exit (Short, 3 ATRs) 39.02
Upper Bollinger Bands 39.09
Lower Bollinger Band 33.40
Percent B (%b) 0.01
BandWidth 15.71
MACD Line -0.03
MACD Signal Line 0.60
MACD Histogram -0.63
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 49.7 Million
EPS -3.29
Price-to-Earnings (P/E) Ratio -10.17
Price-to-Sales 296.69
Price-to-Book 2.73
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.44
Resistance 3 (R3) 35.63 35.15 35.11
Resistance 2 (R2) 35.15 34.65 35.06 35.00
Resistance 1 (R1) 34.31 34.34 34.07 34.12 34.89
Pivot Point 33.83 33.83 33.72 33.74 33.83
Support 1 (S1) 32.99 33.33 32.75 32.80 32.03
Support 2 (S2) 32.51 33.02 32.42 31.92
Support 3 (S3) 31.67 32.51 31.81
Support 4 (S4) 31.48